Eterna Therapeutics Inc. (NASDAQ:ERNA – Get Rating)'s stock price dropped 1.7% on Wednesday . The company traded as low as $4.96 and last traded at $4.97. Approximately 11,002 shares traded hands during mid-day trading, a decline of 63% from the average daily volume of 29,360 shares. The stock had previously closed at $5.06.
Eterna Therapeutics Trading Down 1.7 %
The company has a fifty day moving average price of $3.73.
Get
Eterna Therapeutics alerts:
Eterna Therapeutics (NASDAQ:ERNA – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The company reported ($2.49) earnings per share for the quarter.
Insider Buying and Selling
In other Eterna Therapeutics news, Director Nicholas Jason Singer acquired 283,286 shares of the company's stock in a transaction on Friday, December 2nd. The shares were acquired at an average cost of $3.28 per share, with a total value of $929,178.08. Following the completion of the acquisition, the director now directly owns 266,214 shares in the company, valued at $873,181.92. The purchase was disclosed in a legal filing with the SEC, which can be accessed through
this link. In other news, major shareholder John D. Halpern purchased 335,920 shares of the stock in a transaction dated Friday, December 2nd. The shares were purchased at an average cost of $3.28 per share, with a total value of $1,101,817.60. Following the completion of the acquisition, the insider now owns 450,961 shares in the company, valued at approximately $1,479,152.08. The transaction was disclosed in a document filed with the SEC, which is available at
this link. Also, Director Nicholas Jason Singer acquired 283,286 shares of the firm's stock in a transaction that occurred on Friday, December 2nd. The stock was bought at an average price of $3.28 per share, for a total transaction of $929,178.08. Following the completion of the transaction, the director now owns 266,214 shares of the company's stock, valued at approximately $873,181.92. The disclosure for this purchase can be found
here. 20.50% of the stock is owned by insiders.
About Eterna Therapeutics
(Get Rating)
Eterna Therapeutics Inc, a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease.
Further Reading
- Get a free copy of the StockNews.com research report on Eterna Therapeutics (ERNA)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for Eterna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eterna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
